Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
Biologics
Branded Benlysta DTC campaign ready to roll out
Marc Iskowitz
October 26, 2011
New online and print DTC advertising targeting US patients with lupus will appear "within weeks," said executives from Human Genome Sciences. Can the campaign revive blockbuster fortunes for Benlysta?
GSK, HGS cleared to launch lupus drug with unrestricted label
Marc Iskowitz
March 10, 2011
When co-marketers Human Genome Sciences and GlaxoSmithKline launch newly approved lupus drug Benlysta later this month, reps will be able to tout a broad label.
Generic Lovenox drags down Sanofi sales
Marc Iskowitz
November 01, 2010
Sanofi-Aventis said US sales of anti-thrombotic Lovenox were cut nearly in half by the launch of generic competition, an indication hospitals are showing little hesitation in using the copycat version.
Amgen deploys up to 1,000 reps on Prolia approval
Ben Comer
June 03, 2010
Amgen has deployed "500 to 1,000" reps in support of Prolia (denosumab), a biologic osteoporosis treatment that received FDA approval on June 1. The drug was approved in the European Union on May 28.
What's behind Humira's bullish forecast?
Marc Iskowitz
May 04, 2010
A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.
FDA says competing biologic ads both misled
Ben Comer
April 07, 2010
One is a sales aid, and one is a consumer brochure, but both ads -- for CSL Behring's Zemaira and for Talecris' Prolastin -- are false or misleading, FDA said in a pair of untitled letters.
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Humira on solid ground, analysts say, despite vote on Pfizer hopeful
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
Wolters Kluwer deals health analytics unit to private equity firm
RX-to-OTC proposal gets mixed reviews
Makers of pain pills, advocacy groups at center of Senate probe
Pharmas are from Mars, Payers are from Venus
Study: Young Latinas are key decision makers, prefer English
Coach vs. cancer in BMS-backed awareness effort
Indian conglomerate buys Manhattan Research parent for $635m
Harvard urges faculty to ditch journals
Study: Young Latinas are key decision makers, prefer English
Pharma Report 2012: Get Back in Shape
Massachusetts gift ban under attack (again)
Enbrel reps risk layoff, as Pfizer calls early end to US selling
Pfizer, Crestor tops for global promotional spend in 2011
Novo Nordisk plans US hiring spree as Q1 sales jump 10%
Med Ed Report: Show Me the Money
Wolters Kluwer deals health analytics unit to private equity firm
Humira on solid ground, analysts say, despite vote on Pfizer hopeful
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Goodbye Plavix, hello competition
Indian conglomerate buys Manhattan Research parent for $635m
Sales forces shrank in 2011, but not everywhere
National plan seeks Alzheimer's treatment by 2025
Popular Topics
Acquisition
Adherence
App
Celebrity
Clinical Trial
Co-Marketing
Conflict Of Interest
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
Education & Awareness
FDA
Government
Guidance
Health Plans
HMOs
Hospitals
Insurers
Law
Marketing Research
Mobile
Sales Force